SCM
ZNTL icon

Stonepine Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Stonepine Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$784K Sell
161,583
-107,517
-40% -$429K 0.44% 52
2026
Q1 		$630K Sell
269,100
-194,600
-42% -$503K 0.25% 51
2025
Q4 		$626K Buy
463,700
+9,900
+2% +$14.4K 0.46% 46
2025
Q3 		$685K Buy
453,800
+344,790
+316% +$517K 0.56% 34
2025
Q2 		$126K Buy
109,010
+49,010
+82% +$64.6K 0.12% 57
2025
Q1 		$95.4K Buy
+60,000
New +$129K 0.09% 57

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Stonepine Capital Management's ZNTL Position: Q2 2026 in Review

Stonepine Capital Management reduced its Zentalis Pharmaceuticals (ZNTL) stake by 40% in Q2 2026, selling an estimated $429K and leaving 161,583 shares worth $784K. The position accounts for 0.44% of the portfolio, ranked #52.

Stonepine Capital Management first reported a position in ZNTL in Q1 2025 and has held it in 6 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Stonepine Capital Management held 161,583 shares of Zentalis Pharmaceuticals worth $784K as of Q2 2026.
  • Stonepine Capital Management sold 107,517 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $429K.
  • Zentalis Pharmaceuticals made up 0.44% of Stonepine Capital Management's portfolio in Q2 2026, its #52 holding.
  • Stonepine Capital Management first reported a position in Zentalis Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.